Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04698187
Title CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications

melanoma

Therapies

Nivolumab + QbG10

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.